Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane

Elly V. Barry, Lynda M. Vrooman, Suzanne E. Dahlberg, Donna S. Neuberg, Barbara L. Asselin, Uma H. Athale, Luis A. Clavell, Eric C. Larsen, Albert Moghrabi, Yvan Samson, Marshall A. Schorin, Harvey J. Cohen, Steven E Lipshultz, Stephen E. Sallan, Lewis B. Silverman

Research output: Contribution to journalArticle

90 Citations (Scopus)

Abstract

Purpose: Dexrazoxane is a drug used to prevent anthracycline-induced cardiotoxicity. A recent report found an association between the use of dexrazoxane and the risk of developing secondary malignant neoplasms (SMNs) in children with Hodgkin's disease. We report the absence of an association of SMNs in children with acute lymphoblastic leukemia (ALL) treated on Dana-Farber Cancer Institute ALL Consortium Protocol 95-01. Patients and Methods: Two hundred five children with high-risk (HR) ALL were randomly assigned to receive doxorubicin alone (n = 100) or doxorubicin with dexrazoxane (n = 105) during the induction and intensification phases of multiagent chemotherapy. We compared incidence of SMNs in these two groups. Results: With a median follow-up of 6.2 years, no differences in the incidence of SMNs were noted between the group that received dexrazoxane and the group that did not (P = .66). One SMN (a melanoma located outside of the cranial radiation field) occurred in a patient who was randomly assigned to doxorubicin alone. No SMNs were observed in patients randomly assigned to receive dexrazoxane. Conclusion: Dexrazoxane was not associated with an increased risk of SMNs in children treated for HR ALL. Given the potential importance of dexrazoxane as a cardioprotectant, we recommend that dexrazoxane continue to be used and studied in doxorubicin-containing pediatric regimens.

Original languageEnglish
Pages (from-to)1106-1111
Number of pages6
JournalJournal of Clinical Oncology
Volume26
Issue number7
DOIs
StatePublished - Mar 1 2008
Externally publishedYes

Fingerprint

Dexrazoxane
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Doxorubicin
Neoplasms
Anthracyclines
Incidence
Hodgkin Disease
Melanoma
Radiation
Pediatrics
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Barry, E. V., Vrooman, L. M., Dahlberg, S. E., Neuberg, D. S., Asselin, B. L., Athale, U. H., ... Silverman, L. B. (2008). Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. Journal of Clinical Oncology, 26(7), 1106-1111. https://doi.org/10.1200/JCO.2007.12.2481

Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. / Barry, Elly V.; Vrooman, Lynda M.; Dahlberg, Suzanne E.; Neuberg, Donna S.; Asselin, Barbara L.; Athale, Uma H.; Clavell, Luis A.; Larsen, Eric C.; Moghrabi, Albert; Samson, Yvan; Schorin, Marshall A.; Cohen, Harvey J.; Lipshultz, Steven E; Sallan, Stephen E.; Silverman, Lewis B.

In: Journal of Clinical Oncology, Vol. 26, No. 7, 01.03.2008, p. 1106-1111.

Research output: Contribution to journalArticle

Barry, EV, Vrooman, LM, Dahlberg, SE, Neuberg, DS, Asselin, BL, Athale, UH, Clavell, LA, Larsen, EC, Moghrabi, A, Samson, Y, Schorin, MA, Cohen, HJ, Lipshultz, SE, Sallan, SE & Silverman, LB 2008, 'Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane', Journal of Clinical Oncology, vol. 26, no. 7, pp. 1106-1111. https://doi.org/10.1200/JCO.2007.12.2481
Barry, Elly V. ; Vrooman, Lynda M. ; Dahlberg, Suzanne E. ; Neuberg, Donna S. ; Asselin, Barbara L. ; Athale, Uma H. ; Clavell, Luis A. ; Larsen, Eric C. ; Moghrabi, Albert ; Samson, Yvan ; Schorin, Marshall A. ; Cohen, Harvey J. ; Lipshultz, Steven E ; Sallan, Stephen E. ; Silverman, Lewis B. / Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. In: Journal of Clinical Oncology. 2008 ; Vol. 26, No. 7. pp. 1106-1111.
@article{c90589188be34eb59be545997c6c879b,
title = "Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane",
abstract = "Purpose: Dexrazoxane is a drug used to prevent anthracycline-induced cardiotoxicity. A recent report found an association between the use of dexrazoxane and the risk of developing secondary malignant neoplasms (SMNs) in children with Hodgkin's disease. We report the absence of an association of SMNs in children with acute lymphoblastic leukemia (ALL) treated on Dana-Farber Cancer Institute ALL Consortium Protocol 95-01. Patients and Methods: Two hundred five children with high-risk (HR) ALL were randomly assigned to receive doxorubicin alone (n = 100) or doxorubicin with dexrazoxane (n = 105) during the induction and intensification phases of multiagent chemotherapy. We compared incidence of SMNs in these two groups. Results: With a median follow-up of 6.2 years, no differences in the incidence of SMNs were noted between the group that received dexrazoxane and the group that did not (P = .66). One SMN (a melanoma located outside of the cranial radiation field) occurred in a patient who was randomly assigned to doxorubicin alone. No SMNs were observed in patients randomly assigned to receive dexrazoxane. Conclusion: Dexrazoxane was not associated with an increased risk of SMNs in children treated for HR ALL. Given the potential importance of dexrazoxane as a cardioprotectant, we recommend that dexrazoxane continue to be used and studied in doxorubicin-containing pediatric regimens.",
author = "Barry, {Elly V.} and Vrooman, {Lynda M.} and Dahlberg, {Suzanne E.} and Neuberg, {Donna S.} and Asselin, {Barbara L.} and Athale, {Uma H.} and Clavell, {Luis A.} and Larsen, {Eric C.} and Albert Moghrabi and Yvan Samson and Schorin, {Marshall A.} and Cohen, {Harvey J.} and Lipshultz, {Steven E} and Sallan, {Stephen E.} and Silverman, {Lewis B.}",
year = "2008",
month = "3",
day = "1",
doi = "10.1200/JCO.2007.12.2481",
language = "English",
volume = "26",
pages = "1106--1111",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "7",

}

TY - JOUR

T1 - Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane

AU - Barry, Elly V.

AU - Vrooman, Lynda M.

AU - Dahlberg, Suzanne E.

AU - Neuberg, Donna S.

AU - Asselin, Barbara L.

AU - Athale, Uma H.

AU - Clavell, Luis A.

AU - Larsen, Eric C.

AU - Moghrabi, Albert

AU - Samson, Yvan

AU - Schorin, Marshall A.

AU - Cohen, Harvey J.

AU - Lipshultz, Steven E

AU - Sallan, Stephen E.

AU - Silverman, Lewis B.

PY - 2008/3/1

Y1 - 2008/3/1

N2 - Purpose: Dexrazoxane is a drug used to prevent anthracycline-induced cardiotoxicity. A recent report found an association between the use of dexrazoxane and the risk of developing secondary malignant neoplasms (SMNs) in children with Hodgkin's disease. We report the absence of an association of SMNs in children with acute lymphoblastic leukemia (ALL) treated on Dana-Farber Cancer Institute ALL Consortium Protocol 95-01. Patients and Methods: Two hundred five children with high-risk (HR) ALL were randomly assigned to receive doxorubicin alone (n = 100) or doxorubicin with dexrazoxane (n = 105) during the induction and intensification phases of multiagent chemotherapy. We compared incidence of SMNs in these two groups. Results: With a median follow-up of 6.2 years, no differences in the incidence of SMNs were noted between the group that received dexrazoxane and the group that did not (P = .66). One SMN (a melanoma located outside of the cranial radiation field) occurred in a patient who was randomly assigned to doxorubicin alone. No SMNs were observed in patients randomly assigned to receive dexrazoxane. Conclusion: Dexrazoxane was not associated with an increased risk of SMNs in children treated for HR ALL. Given the potential importance of dexrazoxane as a cardioprotectant, we recommend that dexrazoxane continue to be used and studied in doxorubicin-containing pediatric regimens.

AB - Purpose: Dexrazoxane is a drug used to prevent anthracycline-induced cardiotoxicity. A recent report found an association between the use of dexrazoxane and the risk of developing secondary malignant neoplasms (SMNs) in children with Hodgkin's disease. We report the absence of an association of SMNs in children with acute lymphoblastic leukemia (ALL) treated on Dana-Farber Cancer Institute ALL Consortium Protocol 95-01. Patients and Methods: Two hundred five children with high-risk (HR) ALL were randomly assigned to receive doxorubicin alone (n = 100) or doxorubicin with dexrazoxane (n = 105) during the induction and intensification phases of multiagent chemotherapy. We compared incidence of SMNs in these two groups. Results: With a median follow-up of 6.2 years, no differences in the incidence of SMNs were noted between the group that received dexrazoxane and the group that did not (P = .66). One SMN (a melanoma located outside of the cranial radiation field) occurred in a patient who was randomly assigned to doxorubicin alone. No SMNs were observed in patients randomly assigned to receive dexrazoxane. Conclusion: Dexrazoxane was not associated with an increased risk of SMNs in children treated for HR ALL. Given the potential importance of dexrazoxane as a cardioprotectant, we recommend that dexrazoxane continue to be used and studied in doxorubicin-containing pediatric regimens.

UR - http://www.scopus.com/inward/record.url?scp=41949096690&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41949096690&partnerID=8YFLogxK

U2 - 10.1200/JCO.2007.12.2481

DO - 10.1200/JCO.2007.12.2481

M3 - Article

C2 - 18309945

AN - SCOPUS:41949096690

VL - 26

SP - 1106

EP - 1111

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 7

ER -